OTCMKTS:PARD Poniard Pharmaceuticals (PARD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About Poniard Pharmaceuticals Stock (OTCMKTS:PARD) 30 days 90 days 365 days Advanced Chart Get PARD alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume301 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Poniard Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the research and development of targeted therapies for oncology and immuno-oncology. The company’s scientific efforts center on small-molecule drug candidates designed to inhibit tumor growth pathways and enhance anti-tumor immune responses. Poniard seeks to address unmet medical needs by advancing novel mechanisms of action in cancer treatment, with an emphasis on selecting compounds that exhibit both efficacy and safety in preclinical studies. Poniard’s product pipeline comprises lead candidates that have progressed through discovery and preclinical development, each aimed at modulating key signaling pathways involved in cancer cell survival and immune evasion. The company employs a combination of in-house research capabilities and external collaborations with academic laboratories to accelerate the identification and optimization of its therapeutic agents. This approach allows Poniard to leverage specialized expertise and cutting-edge technologies in assay development and medicinal chemistry. Incorporated in Delaware and headquartered in Seattle, Washington, Poniard Pharmaceuticals operates primarily within the United States while evaluating opportunities for strategic partnerships abroad. The company’s leadership team brings together seasoned professionals in drug discovery, translational research, and clinical development, each contributing years of experience in advancing oncology programs from early-stage research through regulatory filings.AI Generated. May Contain Errors. Read More Receive PARD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poniard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PARD Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com PARD Stock Analysis - Frequently Asked Questions How do I buy shares of Poniard Pharmaceuticals? Shares of PARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Poniard Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Poniard Pharmaceuticals investors own include Plug Power (PLUG), Devon Energy (DVN), DOW (DOW), Chevron (CVX), Corteva (CTVA), Constellation Energy (CEG) and Brenmiller Energy (BNRG). Company Calendar Today9/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:PARD CIK755806 Webwww.poniard.com Phone(206) 281-7001Fax650-583-3789Employees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.32 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:PARD) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredApple’s falling behindApple just posted record-breaking results, yet its stock barely moved — because in today’s market, investors o...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poniard Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poniard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.